BMY Q2 2025 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q2 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$12.3B+0.6% YoY

Gross Profit

$8.1B65.8% margin

Operating Income

$4.1B33.6% margin

Net Income

$1.3B10.7% margin

EPS (Diluted)

$0.64

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

$3.9B

Free Cash Flow

$3.6B

Stock-Based Comp.

$137M

Balance Sheet

Total Assets

$94.7B

Total Liabilities

$77.2B

Stockholders' Equity

$17.4B

Cash & Equivalents

$12.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.3B	$12.2B	+0.6%
Gross Profit	$8.1B	$6.8B	+18.7%
Operating Income	$4.1B	$2.6B	+59.3%
Net Income	$1.3B	$1.7B	-22.0%

Revenue Segments

Eliquis

$3.7B30%

Opdivo

$2.6B21%

Orencia

$963M8%

Revlimid

$838M7%

Yervoy

$728M6%

Pomalyst/Imnovid

$708M6%

Reblozyl

$568M5%

Other Growth Brands

$470M4%

Breyanzi

$344M3%

Opdualag

$284M2%

Camzyos

$260M2%

Other Legacy Brands

$223M2%

Zeposia

$150M1%

Sprycel

$120M1%

Abraxane

$105M1%

Abecma

$87M1%

Sotyktu

$70M1%

Krazati

$48M0%

Cobenfy

$35M0%

Opdivo Ovantig

$30M0%

Geographic Segments

UNITED STATES

$8.5B69%

Rest Of World

$3.5B28%

Other Region

$270M2%